Merck's ragweed pollen allergy drug gets U.S. approval

Send a link to a friend  Share

[April 18, 2014] 

(Reuters) The U.S. Food and Drug Administration has approved Merck & Co's pollen allergy drug Ragwitek.

The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis. (http://r.reuters.com/nyg68v)

The approval for Ragwitek comes days after U.S. regulatory approval for Merck's grass pollen allergy drug Grastek.

Merck's Grastek will compete with Stallergenes SA's immunotherapy treatment for five types of grass pollen, which was approved by the FDA earlier this month.

(Reporting by Shailesh Kuber; editing by Sriraj Kalluvila)

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Recent articles

Back to top